Detalles de la búsqueda
1.
Carfilzomib, thalidomide, and dexamethasone is safe and effective in relapsed and/or refractory multiple myeloma: final report of the single arm, multicenter phase II ALLG MM018/AMN002 study.
Haematologica
; 2024 Jan 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-38235519
2.
Challenges associated with test dose pharmacokinetic predictions of high dose melphalan exposure in patients with multiple myeloma.
Eur J Clin Pharmacol
; 78(12): 1911-1921, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36205743
3.
A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy.
Blood
; 132(1): 49-58, 2018 07 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29666118
4.
Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14).
Haematologica
; 107(1): 321-325, 2022 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34587718
5.
Formalising multidisciplinary peer review: developing a haematological malignancy-specific electronic proforma and standard operating procedure to facilitate procedural efficiency and evidence-based clinical practice.
Intern Med J
; 47(5): 542-548, 2017 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-27753208
6.
Statin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: An exploratory analysis of the PRIMA cohort study.
Am J Hematol
; 91(4): 410-5, 2016 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-26799234
7.
Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma.
Clin Hematol Int
; 5(1): 43-51, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36656461
8.
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.
Lancet
; 377(9759): 42-51, 2011 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21176949
9.
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR.
Clin Lymphoma Myeloma Leuk
; 20(8): 509-518, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32482541
10.
Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS).
Leukemia
; 34(7): 1840-1852, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32024950
11.
Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study.
J Clin Oncol
; 37(31): 2815-2824, 2019 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31339826
12.
A Novel Case of Symptomatic BK Viraemia in a Patient Undergoing Treatment for Hodgkin Lymphoma.
Case Rep Infect Dis
; 2014: 909516, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25057419
13.
Differential identification of a rare form of platelet-type (pseudo-) von Willebrand disease (VWD) from Type 2B VWD using a simplified ristocetin-induced-platelet-agglutination mixing assay and confirmed by genetic analysis.
Br J Haematol
; 139(4): 623-6, 2007 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-17916098
14.
Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants.
J Clin Oncol
; 29(23): 3194-200, 2011 Aug 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-21747087
Resultados
1 -
14
de 14
1
Próxima >
>>